These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10761169)

  • 1. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers.
    Viegas TX; Omura GA; Stoltz RR; Kisicki J
    J Clin Pharmacol; 2000 Apr; 40(4):410-20. PubMed ID: 10761169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
    Kilpatrick JM; Morris PE; Serota DG; Phillips D; Moore DR; Bennett JC; Babu YS
    Int Immunopharmacol; 2003 Apr; 3(4):541-8. PubMed ID: 12689658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in monkey plasma purines induced by repeated doses of CI-1000, a novel inhibitor of purine nucleoside phosphorylase.
    Robertson DG; Urda ER; Bleavins MR; Lalwani ND
    Adv Exp Med Biol; 1994; 370():173-7. PubMed ID: 7660884
    [No Abstract]   [Full Text] [Related]  

  • 5. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
    Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
    Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
    Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
    Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of nucleoside degradation in monkey whole blood in vitro by CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor.
    Gilbertsen RB; Dong MK
    Adv Exp Med Biol; 1994; 370():167-71. PubMed ID: 7660883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
    Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
    Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/pharmacodynamics of CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor, in rats and monkeys.
    Hallak H; Hayes A; Dong M; Gilbertsen R; Guttendorf R
    Adv Exp Med Biol; 1994; 370():161-5. PubMed ID: 7660882
    [No Abstract]   [Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955.
    Gilbertsen RB; Josyula U; Sircar JC; Dong MK; Wu WS; Wilburn DJ; Conroy MC
    Biochem Pharmacol; 1992 Sep; 44(5):996-9. PubMed ID: 1530667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids.
    Yan J; Lu Z; Walsh GM; Wheeler RH; Diasio RB
    J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):295-303. PubMed ID: 9106056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
    Umemura K; Kondo K; Ikeda Y; Kobayashi T; Urata Y; Nakashima M
    Br J Clin Pharmacol; 1997 Jun; 43(6):613-8. PubMed ID: 9205821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
    Bantia S; Montgomery JA; Johnson HG; Walsh GM
    Immunopharmacology; 1996 Oct; 35(1):53-63. PubMed ID: 8913795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
    Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
    J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.